p3

Cambridge Healthtech Institute’s 9th Annual

Bispecific Antibody Therapeutics
( 双特异性抗体疗法 )

Combination Therapy & Engineering Multi-Specificity

1月23日~24日

Part of the Antibody Therapeutics pipeline

CHI’s Bispecific Antibody Therapeutics conference explores the challenges of engineering multi-specificity to achieve more effective therapies that bind to at least two targets simultaneously. The conference examines how these molecules are used to fight a wide array of diseases, as well as in combination therapy for enhanced effects in the fight against cancer. Along with increased efficacy, Bispecific Antibody Therapeutics can also optimize expenses by reducing the cost of development and clinical trials. Case studies highlight novel engineering approaches and platform constructs that improve safety, stability, enhanced targeting, and manufacturability.

Preliminary Agenda

ENGINEERING MULTI-SPECIFICITY

KEYNOTE PRESENTATION: The Landscape of Multi-Specific Antibodies

Partha S. Chowdhury, PhD, Senior Director and Head, Antibody Discovery, Sanofi Genzyme

Building Blocks for Bispecific and Trispecific Antibodies

Stephen Demarest, PhD, Senior Research Fellow, Protein Biosciences, Eli Lilly & Co.

Maximizing Therapeutic Potential of Bispecific Antibodies and Cytokines by Affinity and Avidity Engineering

David E. Szymkowski, PhD, Vice President, Cell Biology, Xencor, Inc.

Development of NM21-1480, A Trispecific Anti-PD-L1x4-1BBxhSA Antibody Fragment

Sebastian Meyer, PhD, Chief Operating Officer, Numab Therapeutics AG

T CELL ENGAGING BISPECIFICS TO FIGHT CANCER

Advancing a Novel T Cell Engaging Bispecific Antibody that Induces Lysis of Small Cell Lung Cancer Cells In Vitro and Shows Potent T Cell Re-Directed Anti-Tumor Activity In Vivo

Justin Scheer, PhD, Director, Protein and Antibody Engineering, Boehringer Ingelheim

Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3-Bispecifics and CAR T Cells

David J. DiLillo, PhD, Senior Staff Scientist, Immuno-Oncology, Regeneron Pharmaceuticals

HARNESSING THE IMMUNE SYSTEM

Modulating the Immune System with Multi-Specific Antibodies in Cancer

Nathan Trinklein, PhD, Chief Technology Officer, TeneoBio, Inc.

Engineered Multispecific Antibodies for Targeted Inhibition of Cancer Metastasis

Jamie B. Spangler, PhD, Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University

ATOR-1015, A Bispecific CTLA-4 x OX40 Antibody, Induces Anti-Tumor Effects Through Tumor-Directed Immune Activation

Christina Furebring, PhD, Senior Vice President, Preclinical Development, Alligator Bioscience



* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English






2020年会议节目和培训研讨会


免费电子邮件通知服务